Epiminder (ASX:EPI) Notes Receivable: A$0.00 Mil (As of Dec. 2025)


ASX:EPI Epiminder Ltd ASX:EPI
17 GF Score
Price A$0.32
View Full Analysis

What is Epiminder Notes Receivable?

Epiminder ASX:EPI +1.59% 17 Notes Receivable is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:EPI with a GF Score™ of 17/100.

Epiminder's Notes Receivable for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Epiminder Notes Receivable Historical Data

* Premium members only.

The historical data trend for Epiminder's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Epiminder Notes Receivable Chart

Epiminder Annual Data
Trend Jun23 Jun24 Jun25
Notes Receivable
0.00 0.00 0.00

Epiminder Semi-Annual Data
Jun23 Jun24 Jun25 Dec25
Notes Receivable 0.00 0.00 0.00 0.00
ASX:EPI
17GF Score
Epiminder Ltd ASX:EPI
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Epiminder Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of A$0.00 Mil mean?
Epiminder (ASX:EPI) has a Notes Receivable of A$0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Epiminder and its competitors.
Is Epiminder's Notes Receivable too high?
Epiminder's current Notes Receivable is A$0.00 Mil. Overall, Epiminder has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Epiminder's Notes Receivable compare to ABT and SYK?
Epiminder's Notes Receivable of A$0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Epiminder and its competitors. Epiminder's current Notes Receivable is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epiminder stock overvalued right now?
Epiminder (ASX:EPI) has a current Notes Receivable of A$0.00 Mil. The current Notes Receivable is A$0.00 Mil. Epiminder's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Epiminder (ASX:EPI), the current Notes Receivable is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Epiminder Business Description

Address 525 Collins Street, 210 West Podium, Mezzanine 2, Melbourne, VIC, AUS, 3000
Epiminder Ltd is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy. Its system is a sub-scalp device for continuous monitoring of electrographic brain activity and a set of information solutions, providing patients and their healthcare professionals with detailed data over an extended period.
17GF Score

Get the complete analysis for ASX:EPI

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.32
Price